Researchers who were responsible for testing Pfizer’s vaccine at several sites in the fall of 2020 say speed of trials may have come at the expense of data integrity and patient safety.
The following is an excerpt taken from an article in the British Medical Journal (BMJ):
A regional director who was employed at the research organisation Ventavia Research Group has told The BMJ that the company falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer’s pivotal phase III trial.
Staff who conducted quality control checks were overwhelmed by the volume of problems they were finding. After repeatedly notifying Ventavia of these problems, the regional director, Brook Jackson, emailed a complaint to the US Food and Drug Administration (FDA).
Ventavia fired her later the same day. Jackson has provided The BMJ with dozens of internal company documents, photos, audio recordings, and emails. (Continued...)
Read entire BMJ article here